首頁 > 市場調查報告書 > 製藥

慢性腎臟病（CKD）市場規模、佔有率和成長分析（按診斷、治療方法、給藥途徑、最終用戶和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1915755

慢性腎臟病（CKD）市場規模、佔有率和成長分析（按診斷、治療方法、給藥途徑、最終用戶和地區分類）—產業預測（2026-2033 年）

Chronic Kidney Disease Market Size, Share, and Growth Analysis, By Diagnosis (Blood Test, Urine Test), By Treatment (Drugs, Dialysis), By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月02日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球慢性腎臟病(CKD) 市場規模預計在 2024 年達到 169.3 億美元，從 2025 年的 203.4 億美元成長到 2033 年的 880.3 億美元，在預測期（2026-2033 年）內複合年成長率為 20.1%。

慢性腎臟病（CKD）市場正因糖尿病和高血壓盛行率的不斷上升而持續成長，而糖尿病和高血壓正是CKD的主要誘發因素。全球人口老化進一步加劇了這個問題，因為腎功能會隨著老齡化的成長而下降。患者和醫療專業人員對CKD的認知不斷提高，促使CKD的早期發現和診斷，最終推動了對治療藥物、干預策略和先進技術治療方法的需求。這一持續趨勢凸顯了有效管理方案對於應對日益嚴重的CKD負擔的必要性，並為市場相關人員創造了巨大的機會。隨著醫療保健系統不斷適應這些挑戰，預計市場將繼續擴張，這也凸顯了治療方案創新和可近性的重要性。

全球慢性腎臟病市場促進因素

全球慢性腎臟病市場受到糖尿病和高血壓盛行率不斷上升的顯著影響，這兩種疾病是導致腎臟損傷的主要原因。隨著患有這些慢性疾病的人群持續成長，對有效治療方法的需求也將相應增加。糖尿病和高血壓發病率的上升將導致慢性腎臟病病患者數量的增加，這將成為推動市場發展的因素。這些慢性疾病與腎臟健康之間的關聯凸顯了開發先進治療方法和介入措施以應對和控制這一日益嚴峻的健康挑戰的必要性。

全球慢性腎臟病市場限制因素

全球慢性腎臟病市場面臨嚴峻挑戰，其中晚期慢性腎臟病治療費用高昂是主要原因。透析和腎臟移植等治療費用昂貴，會給患者帶來沉重的經濟負擔，尤其是在醫療保障有限的地區。這種經濟負擔不僅阻礙了患者獲得所需的治療，還會影響一個國家醫療體系的整體預算。因此，解決慢性腎臟病治療中的這些經濟難題對於改善患者預後和確保患者公平獲得治療至關重要。

全球慢性腎臟病市場趨勢

全球慢性腎臟病市場正呈現出顯著的趨勢，即早期診斷和積極干預，治療重點從臨終關懷轉向預防措施。這種模式轉移強調了篩檢高風險族群以促進疾病早期發現的重要性。隨著醫療保健體系的不斷發展，人們對旨在延緩疾病進展、改善患者預後的創新治療方案的需求日益成長，理想情況下，這些方案應在患者需要透析之前發揮作用。這種積極主動的治療方法不僅能提升病患的生活品質，還能減輕醫療資源的整體負擔，凸顯了慢性腎臟病管理領域的變革性觀點。

血液檢查
- 血清肌酸酐檢測
- 腎絲球過濾率（GFR）測試
- 血中尿素氮（BUN）檢測
- 電解質測試
尿液檢查
- 尿液分析
- 24小時尿液收集
- 尿蛋白檢測
- 尿液白蛋白肌酸酐比值（ACR）
影像檢查
- 超音波
- 電腦斷層掃描
- MRI
- X光
切片檢查
- 經皮皮腎切片檢查
- 開放式切片檢查
- 腹腔鏡切片檢查

全球慢性腎臟病（CKD）市場規模（依治療方法分類），複合年成長率（2026-2033 年）

藥物
透析
腎臟移植
ACE抑制劑
血液檢查
其他治療方法

全球慢性腎臟病（CKD）市場規模（依給藥途徑分類），複合年成長率（2026-2033 年）

口服
靜脈注射
皮下注射

全球慢性腎臟病（CKD）市場規模（按最終用戶分類），複合年成長率（2026-2033 年）

醫院和診所
門診手術中心（ASC）
透析中心
其他最終用戶

全球慢性腎臟病（CKD）市場規模、複合年成長率（2026-2033）

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

AstraZeneca（United Kingdom）
Amgen Inc.（United States）
Bayer AG（Germany）
Fresenius Medical Care（Germany）
DaVita Inc.（United States）
F. Hoffmann-La Roche Ltd.（Switzerland）
Baxter International Inc.（United States）
Novartis AG（Switzerland）
Johnson & Johnson（United States）
Pfizer Inc.（United States）
GlaxoSmithKline plc（GSK）（United Kingdom）
AbbVie Inc.（United States）
Boehringer Ingelheim International GmbH（Germany）
Travere Therapeutics（United States）
Vera Therapeutics（United States）
ProKidney（United States）
Akebia Therapeutics（United States）
Calliditas Therapeutics AB（Sweden）
Becton, Dickinson and Company（BD）（United States）
Renalytix Plc（United Kingdom）

結論與建議

簡介目錄

Product Code: SQMIG35D2374

Global Chronic Kidney Disease Market size was valued at USD 16.93 Billion in 2024 and is poised to grow from USD 20.34 Billion in 2025 to USD 88.03 Billion by 2033, growing at a CAGR of 20.1% during the forecast period (2026-2033).

The market for chronic kidney disease (CKD) is experiencing growth due to the increasing prevalence of diabetes and hypertension, which are primary contributors to CKD. The global aging population further exacerbates this issue, as kidney function typically declines with age. Heightened awareness among patients and healthcare professionals regarding CKD leads to earlier detection and diagnosis, ultimately driving demand for therapeutic drugs, intervention strategies, and advanced technological treatments. This ongoing trend underscores the necessity for effective management solutions to address the growing burden of CKD, creating significant opportunities for market players. As healthcare systems adapt to these challenges, the market is poised for continued expansion, emphasizing the importance of innovation and accessibility in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Kidney Disease Market Segments Analysis

Global Chronic Kidney Disease Market is segmented by Diagnosis, Treatment, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, Imaging Test and Kidney Biopsy. Based on Treatment, the market is segmented into Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test and Other Treatments. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on End User, the market is segmented into Hospital and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is significantly influenced by the increasing prevalence of diabetes and hypertension, both of which are primary contributors to kidney damage. As the populations affected by these chronic conditions continue to grow, there will be a corresponding rise in the demand for effective treatments. This increasing incidence of both diabetes and high blood pressure will lead to a higher number of individuals diagnosed with chronic kidney disease, thereby driving the market forward. The link between these chronic illnesses and kidney health highlights the necessity for advanced therapies and interventions to manage and address the escalating health challenges.

Restraints in the Global Chronic Kidney Disease Market

The Global Chronic Kidney Disease market faces significant challenges due to the high costs associated with managing advanced stages of the disease. Treatments such as dialysis and kidney transplants entail substantial financial investments, which can create a considerable burden for patients, particularly in regions with limited healthcare coverage. This financial strain not only hinders patient access to necessary care but also impacts the overall budgets of national health systems. Consequently, addressing these economic constraints is crucial for improving patient outcomes and ensuring equitable access to treatment options in the realm of chronic kidney disease management.

Market Trends of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is witnessing a significant trend towards early diagnosis and proactive intervention, shifting the focus from late-stage treatment to preventive measures. This paradigm shift emphasizes the importance of screening high-risk populations to facilitate timely identification of the disease. As healthcare systems evolve, there is a rising demand for innovative therapeutic solutions designed to slow disease progression and improve patient outcomes, ideally before the need for dialysis arises. This proactive approach not only enhances quality of life for patients but also reduces the overall burden on healthcare resources, highlighting a transformative perspective in chronic kidney disease management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Chronic Kidney Disease Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Blood Test
- Serum Creatinine Test
- Glomerular Filtration Rate (GFR) Test
- Blood Urea Nitrogen (BUN) Test
- Electrolyte Tests
Urine Test
- Urinalysis
- 24-hour Urine Collection
- Urine Protein Test
- Urine Albumin-To-Creatinine Ratio (ACR)
Imaging Test
- Ultrasound
- CT Scan
- MRI
- X-ray
Kidney Biopsy
- Percutaneous Kidney Biopsy
- Open Kidney Biopsy
- Laparoscopic Kidney Biopsy

Global Chronic Kidney Disease Market Size by Treatment & CAGR (2026-2033)

Market Overview
Drugs
Dialysis
Kidney Transplant
ACE Inhibitors
Blood Test
Other Treatments

Global Chronic Kidney Disease Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravenous
Subcutaneous

Global Chronic Kidney Disease Market Size by End User & CAGR (2026-2033)

Market Overview
Hospital and Clinics
Ambulatory Surgery Centers (ASCs)
Dialysis Centers
Other End-Users

Global Chronic Kidney Disease Market Size & CAGR (2026-2033)

North America (Diagnosis, Treatment, Route of Administration, End User)
- US
- Canada
Europe (Diagnosis, Treatment, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Diagnosis, Treatment, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Diagnosis, Treatment, Route of Administration, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Diagnosis, Treatment, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Medical Care (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DaVita Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Travere Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vera Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProKidney (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akebia Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Calliditas Therapeutics AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Renalytix Plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments